Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lactoferrin Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function

NCT06012669
View directory record Official record
Conditions
Immune Health
Interventions
High dose Human Lactoferrin, Low dose Human Lactoferrin, Active Control Bovine Lactoferrin
Dietary Supplement
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Miami, Florida • Port Saint Lucie, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 22, 2026, 12:14 PM EDT
Terminated Phase 1 Interventional

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

NCT01528137
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
talactoferrin, laboratory biomarker analysis
Biological · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 22, 2026, 12:14 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

NCT00706862
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
Duarte, California • Chicago, Illinois • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Effects of rhLactoferrin on Chronic Inflammation in the Elderly

NCT02968992
View directory record Official record
Conditions
Inflammation, Cognitive Deterioration
Interventions
rhLactoferrin, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
70 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 22, 2026, 12:14 PM EDT
Suspended Phase 2Phase 3 Interventional

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase II Growth and Safety Study of an Infant Formula for Healthy Term Infants

NCT04593147
View directory record Official record
Conditions
Infant Development
Interventions
BBN, Brand
Other
Lead sponsor
Building Block Nutritionals, LLC
Industry
Eligibility
1 Day to 14 Days
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 22, 2026, 12:14 PM EDT
Withdrawn Phase 2 Interventional

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

NCT05783180
View directory record Official record
Conditions
COVID-19
Interventions
Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo
Drug
Lead sponsor
Jose David Suarez, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Early Phase 1 Interventional Results available

Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates

NCT01314742
View directory record Official record
Conditions
Ventilator-associated Pneumonia
Interventions
Biotene OralBalance® gel, Sterile Water moisten cotton tipped applicator
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Days and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 22, 2026, 12:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Evaluate the Ability of Lactoferrin to Modulate Iron Homeostasis and Exercise Performance in Exercising Females

NCT07546591
View directory record Official record
Conditions
Iron Deficiencies, Low Ferritin, Iron Deficiency, Exercise Performance of Fit Athletes
Interventions
Lactoferrin 100 mg, Lactoferrin 300 mg, Iron Supplementation (5 mg)
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

NCT00095186
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Recombinant Human Lactoferrin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy

NCT04810546
View directory record Official record
Conditions
Iron-deficiency, Pregnancy Anemia, Obesity
Interventions
Jarrow Formulas Oral Bovine Lactoferrin Supplement
Dietary Supplement
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Alleviation of Common Cold Symptoms

NCT06106880
View directory record Official record
Conditions
Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions
Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet
Drug · Dietary Supplement · Other
Lead sponsor
Applied Biological Laboratories Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Lactoferrin, a Dietary Supplement, vs. Placebo on Respiratory Tract Infections

NCT04713735
View directory record Official record
Conditions
Immune Health
Interventions
Control: Placebo, bovine lactoferrin supplement
Dietary Supplement
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Growth of Infants Fed a New Formula

NCT00937014
View directory record Official record
Conditions
Infant Nutrition
Interventions
standard infant formula, Test formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
11 Days to 17 Days
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Newburgh, Indiana • Owensboro, Kentucky • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 22, 2026, 12:14 PM EDT
Terminated Phase 2 Interventional

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

NCT04621149
View directory record Official record
Conditions
COVID-19
Interventions
chlorine dioxide, zinc acetate, Famotidine, placebo, lactoferrin, green tea extract
Other · Dietary Supplement · Drug
Lead sponsor
Profact, Inc.
Other
Eligibility
20 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Results available

Duration of Effect of Biotene Spray in Patients With Dry Mouth

NCT03663231
View directory record Official record
Conditions
Dry Mouth
Interventions
Biotene, Placebo
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Recombinant Bovine Lactoferrin (rbLf) in Iron Regulation

NCT06428357
View directory record Official record
Conditions
Exercise Performance
Interventions
Recombinant Bovine Lactoferrin, Bovine Milk-Derived Lactoferrin, Placebo
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 22, 2026, 12:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Effera Human Lactoferrin at One Dose Compared to Placebo on Gut Permeability

NCT07035964
View directory record Official record
Conditions
Gut Permeability, Gut Health
Interventions
human lactoferrin, Placebo
Dietary Supplement
Lead sponsor
Helaina Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 22, 2026, 12:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

4-day Plaque Accumulation Model Evaluating Compound Containing Gum

NCT06984744
View directory record Official record
Conditions
Dental Plaque Accumulation
Interventions
MIIP-E2 containing gum, placebo gum without MIIP-E2
Device
Lead sponsor
Lactea Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 22, 2026, 12:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effera Dose Response: Women's Health

NCT07524270
View directory record Official record
Conditions
Womens Health, Menstrual Symptoms
Interventions
Effera® (human equivalent lactoferrin), Placebo
Dietary Supplement · Other
Lead sponsor
Helaina Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 12:14 PM EDT
Not listed Not applicable Interventional

Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.

NCT00377078
View directory record Official record
Conditions
Clostridium Difficile
Interventions
recombinant human lactoferrin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 22, 2026, 12:14 PM EDT
Completed Not applicable Interventional

Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy

NCT01941810
View directory record Official record
Conditions
Anorexia, Cachexia, Malignant Neoplasm, Oral Complications of Chemotherapy
Interventions
bovine lactoferrin supplement, questionnaire administration, quality-of-life assessment, laboratory biomarker analysis
Dietary Supplement · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 22, 2026, 12:14 PM EDT